White Paper

The New Weight Loss Pill: What You Need to Know

The FDA has approved the first oral version of a GLP-1 for the treatment of obesity. What do you need to know about safety, efficacy, and cost?

White Paper Summary

In December 2025, the FDA approved a new oral tablet formulation of Wegovy® (semaglutide), marking the first available GLP-1 drug for the treatment of obesity in an oral formulation.

Like GLP-1 injections, the new oral version is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight. Additionally, the tablets are approved to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease who are either obese or overweight.

The new tablet formulation will be available in dosages of 1.5 mg, 4 mg, 9 mg, and 25 mg. Due to differences in how the body breaks down the oral version versus an injection, the pill comes in a higher dose than the injection and must be taken daily rather than weekly.

 

For more content like this from Healthesystems visit their RxInformer clinical journal website.

Healthesystems is a leading provider of Pharmacy Benefit Management (PBM) & Ancillary Benefits Management programs for the workers' compensation industry.

More from Risk & Insurance